.

Deeper Knowledge, Faster

  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
  • Drug patents in 130+ countries

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Merck
Chubb
Chinese Patent Office
UBS
Federal Trade Commission
US Army
McKesson
Deloitte
Covington
Novartis

Generated: July 26, 2017

DrugPatentWatch Database Preview

Bosutinib monohydrate - Generic Drug Details

« Back to Dashboard

What are the generic drug sources for bosutinib monohydrate and what is the scope of bosutinib monohydrate patent protection?

Bosutinib monohydrate
is the generic ingredient in one branded drug marketed by Pf Prism Cv and is included in one NDA. There are six patents protecting this compound and one Paragraph IV challenge. Additional information is available in the individual branded drug profile pages.

Bosutinib monohydrate has forty-one patent family members in twenty-eight countries.

There are five drug master file entries for bosutinib monohydrate. Two suppliers are listed for this compound.

Summary for Generic Name: bosutinib monohydrate

Tradenames:1
Patents:6
Applicants:1
NDAs:1
Drug Master File Entries: see list5
Suppliers / Packagers: see list2
Bulk Api Vendors: see list3
Clinical Trials: see list122
Patent Applications: see list3
Drug Prices:see low prices
DailyMed Link:bosutinib monohydrate at DailyMed

Pharmacology for Ingredient: bosutinib monohydrate

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Pf Prism Cv
BOSULIF
bosutinib monohydrate
TABLET;ORAL203341-001Sep 4, 2012RXYesYes► Subscribe► Subscribe► Subscribe
Pf Prism Cv
BOSULIF
bosutinib monohydrate
TABLET;ORAL203341-001Sep 4, 2012RXYesYes► Subscribe► SubscribeYY ► Subscribe
Pf Prism Cv
BOSULIF
bosutinib monohydrate
TABLET;ORAL203341-001Sep 4, 2012RXYesYes► Subscribe► SubscribeY ► Subscribe
Pf Prism Cv
BOSULIF
bosutinib monohydrate
TABLET;ORAL203341-001Sep 4, 2012RXYesYes► Subscribe► SubscribeY ► Subscribe
Pf Prism Cv
BOSULIF
bosutinib monohydrate
TABLET;ORAL203341-002Sep 4, 2012RXYesNo► Subscribe► SubscribeYY ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Generic Ingredient: bosutinib monohydrate

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,445,496Crystalline forms of 4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-methoxy-7-[3-(4-methyl-1-pipera- zinyl)propoxy]-3-quinolinecarbonitrile and methods of preparing the same► Subscribe
6,297,258 Substituted 3-cyanoquinolines► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Ingredient: bosutinib monohydrate

Country Document Number Estimated Expiration
Denmark1902029► Subscribe
Russian Federation2007148072► Subscribe
China1874776► Subscribe
World Intellectual Property Organization (WIPO)2005047259► Subscribe
BrazilPI0416289► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Tradename: BOSUTINIB MONOHYDRATE

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0140016 00110Estonia► SubscribePRODUCT NAME: BOSUTINIIB;REG NO/DATE: K(2013)1968 (LOPLIK) 02.04.2013
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Argus Health
Accenture
Julphar
Chinese Patent Office
Boehringer Ingelheim
Federal Trade Commission
Citi
Merck
Dow
Covington

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot